■心理胰岛素抵抗(PIR),这是指糖尿病患者不愿使用胰岛素,是一个经常遇到的临床问题。无针注射(NFI)在加速胰岛素吸收和减轻与注射有关的不良反应方面具有优势。评价皮下注射门冬胰岛素30对2型糖尿病(T2DM)患者PIR和胰岛素用量的影响。
■64名T2DM患者参与了这项随机研究,prospective,打开,交叉研究。门冬胰岛素30通过QS-PNFI和NovoPen5(NP)依次皮下给药。分析了NFI对PIR的影响。胰岛素剂量的差异,血糖变异性,在相似的血糖控制水平下比较了注射安全性.
■NFI给药后,胰岛素治疗态度量表评分下降(53.7±7.3vs.58.9±10.7,p<0.001),胰岛素治疗依从性问卷得分增加(46.3±4.9vs.43.8±7.1,p<0.001),胰岛素治疗满意度问卷得分提高(66.6±10.5vs.62.4±16.5,p<0.001)。在相同的血糖水平下,与NP相比,NFI需要较小剂量的门冬胰岛素30(30.42±8.70vs.33.66±9.13U/d,p<0.001)。血糖变异性指数没有差异(标准偏差,两种注射方法之间的平均血糖波动幅度或变异系数)。与NP相比,NFI并没有增加低血糖的发生率(17.2%vs.14.1%,p=0.774),它降低了硬结的发生率(4.7%vs.23.4%,p=0.002)和泄漏(6.3%vs.20.3%,p=0.022),同时降低疼痛视觉模拟量表评分(2.30±1.58vs.3.11±1.40,p<0.001)。
■NFI可以改善T2DM患者的PIR,并与较小剂量的门冬胰岛素30一起使用,同时保持相同的降血糖作用。
■https://www.chictr.org.cn/,标识符ChiCTR2400083658。
UNASSIGNED: Psychological insulin resistance (PIR), which refers to the reluctance of diabetic patients to use insulin, is a frequently encountered clinical issue. Needle-free injection (NFI) offers advantages in terms of expediting insulin absorption and mitigating adverse reactions related to injection. To evaluate the effects of subcutaneous injection of insulin aspart 30 with NFI on PIR and insulin dosage in patients with type 2 diabetes mellitus (T2DM).
UNASSIGNED: Sixty-four patients with T2DM participated in this randomized, prospective, open, crossover study. Insulin aspart 30 was administered subcutaneously to each subject via QS-P NFI and Novo Pen 5 (NP) successively. The effects of NFI on PIR were analyzed. Differences in insulin dosage, glycemic variability, and injection safety were compared at similar levels of glycemic control.
UNASSIGNED: After the administration of NFI, the insulin treatment attitude scale score decreased (53.7 ± 7.3 vs. 58.9 ± 10.7, p<0.001), the insulin treatment adherence questionnaire score increased (46.3 ± 4.9 vs. 43.8 ± 7.1, p<0.001), and the insulin treatment satisfaction questionnaire score increased (66.6 ± 10.5 vs. 62.4 ± 16.5, p<0.001). At the same blood glucose level, NFI required a smaller dosage of insulin aspart 30 compared with that of NP (30.42 ± 8.70 vs. 33.66 ± 9.13 U/d, p<0.001). There were no differences in glycemic variability indices (standard deviation, mean amplitude of glycemic excursion or coefficient of variation) between the two injection methods. Compared with NP, NFI did not increase the incidence of hypoglycemia (17.2% vs. 14.1%, p=0.774), and it decreased the incidence of induration (4.7% vs. 23.4%, p=0.002) and leakage (6.3% vs. 20.3%, p=0.022) while decreasing the pain visual analog scale score (2.30 ± 1.58 vs. 3.11 ± 1.40, p<0.001).
UNASSIGNED: NFI can improve PIR in patients with T2DM and be used with a smaller dose of insulin aspart 30 while maintaining the same hypoglycemic effect.
UNASSIGNED: https://www.chictr.org.cn/, identifier ChiCTR2400083658.